AI ML Innovations Inc (QB) (AIMLF)

Volume has increased. Price is following. Finally we have some lift !

Very tight trading range for a while now. Waiting for new developments.

AI/ML Innovations Inc. has announced that the United States Patent and Trademark Office has issued a Notice of Allowance for its patent application covering a core machine-learning architecture used in electrocardiogram (ECG) signal processing. The allowed claims protect the company's proprietary methods for denoising ECG signals, identifying wave morphology, and associating these patterns with cardiac rhythm conditions.

Does look good

AI/ML Innovations Inc., through its subsidiary NeuralCloud Solutions Inc., has announced a collaborative pilot program with the Toronto Heart Centre to evaluate CardioYield™, its AI-powered Holter ECG visualization and reporting platform. The study aims to compare CardioYield™ with current industry-standard software, focusing on improvements in analysis efficiency, time savings, and reporting quality. Developed with input from ECG technicians and cardiologists, CardioYield™ leverages advanced AI for automated signal processing and streamlined reporting. The partnership seeks to demonstrate the platform's potential to enhance clinical workflows and diagnostic reliability in Holter ECG analysis.

AI/ML Innovations Inc. has successfully completed an oversubscribed non-brokered private placement, raising a total of $2,128,595. Initially proposing to offer up to 31,000,000 units at $0.05 per unit for gross proceeds of $1,550,000, the company saw increased demand, resulting in the acceptance of subscriptions for 42,571,900 units. Each unit comprises one common share and one warrant, with the warrant exercisable at $0.15 until September 22, 2030. Key insiders, including CEO Paul Duffy and President Peter Kendall, participated in the offering, making it a related party transaction under MI 61-101 regulations. The funds are intended for general working capital, and all issued securities will be under a statutory hold period until January 23, 2026. Additionally, finder's fees and warrants were issued to arm's length parties as part of the transaction.

AIML Innovations announced on Wednesday that it intends to complete a non-brokered private placement offering of up to 31 million units at $0.05 per unit for gross proceeds of up to $1.55 million.
Each unit consists of one common share and one warrant, which will be exercisable into one common share of the company.
Each warrant will have a term of five years and will entitle the holder to purchase one common share at a price of $0.15 per common share following the closing date.
The company intends to use net proceeds for working capital requirements.

Why is this new helpful technology doing so poorly ?

Interesting AI company. Needs industry adoption for value proposition they're offering.

If your pattern recognition software could possibly help the unraveling of the Voinovich Texts, it could go a long way to provide the exposure this company very much needs. JMHO.

AI & Healthcare, looks like a similar run as QNCCF coming here. Just $17m MC. Hold for the move.

https://www.otcmarkets.com/stock/AIMLF

https://www.otcmarkets.com/stock/AIMLF

https://www.otcmarkets.com/stock/AIMLF

EYEWEAR https://www.theglobeandmail.com/investing/markets/stocks/AIMLF/pressreleases/21248620/aiml-innovations-incs-subsidiary-enters-consortium-with-ellisor-international-for-ai-powered-augmented-reality-eyewear-project/

EYEWEAR https://www.theglobeandmail.com/investing/markets/stocks/AIMLF/pressreleases/21248620/aiml-innovations-incs-subsidiary-enters-consortium-with-ellisor-international-for-ai-powered-augmented-reality-eyewear-project/

EYEWEAR https://www.theglobeandmail.com/investing/markets/stocks/AIMLF/pressreleases/21248620/aiml-innovations-incs-subsidiary-enters-consortium-with-ellisor-international-for-ai-powered-augmented-reality-eyewear-project/

Watch AI/ML Innovations (OTC: AIMLF) (CSE: AIML) NEXT SUPER STOCK Video:
https://www.wallstreetreporter.com/2022/05/31/next-super-stock-ai-ml-billion-dollar-patent/

AIMLF’s Health Gauge subsidiary, has recently been granted a patent by the
United States Patent and Trademark Office (US Patent No. 11183303),
titled "Wearable Health Monitors and Methods of Monitoring Health".

The Patent covers Cardiovascular monitoring, Predictive health analysis, Behavioral analysis and 64 other claims,
including use of multiple configurations of wearable health monitors, in conjunction with methods of analyzing bio-signals
and monitoring health metrics (via Health Gauge's AI-driven software) for the purpose of assisting the user in achieving
their personal health and wellness objectives.

AIMLF is reporting advancing growth at its portfolio company Tech2Heal, a European mental health app innovator.
Tech2Heal is positioned for explosive revenue growth
as European healthcare mandates now provide about 2,500 Euro per patient annually for mental wellness.

Tech2Heal has just signed with a French multinational manufacturer, to provide mental wellness
support to their 170,000 employees globally, and additional Enterprise contracts are in the pipeline.

Tim Daniels also updated investors on AIML’s growing pipeline of M&A opportunities in the HealthTech space, which could have a positive impact on maximizing shareholder value in coming months.

Watch AI/ML Innovations (OTC: AIMLF) (CSE: AIML) NEXT SUPER STOCK Video:
https://www.wallstreetreporter.com/2022/05/31/next-super-stock-ai-ml-billion-dollar-patent/

AI/ML Innovations (OTC: AIMLF) (CSE: AIML) Chairman, Tim Daniels: “AI/ML Holds Key Patents
for Multi-Billion Dollar Healthcare Wearables Market”

AI/ML Innovations (OTC: AIMLF), a featured presenter at Wall Street Reporter's "Next Super Stock"
investor conference series, recently updated investors on growth initiatives at AIMLF’s portfolio of
digital health businesses including HealthGauge, a wearable personal health monitoring & management system,
using Artificial Intelligence and Machine Learning, and Tech2Heal a European mental health app innovator.

Of significant interest for investors is AIMLF’s landmark patent position for wearable health monitors -
which could position AIMLF to collect licensing fees and royalties on the $13.8 Billion global
Smart Wearable Healthcare Devices (projected to reach $37.4 Billion by 2028.

Source: Verified Market Research.) AIMLF is now starting to license its technologies to health wearables companies,
and collecting royalties.

With typical royalties of 2% of gross sales,
AIMLF could potentially generate significant recurring revenues from companies infringing on
its broad patent position in the nearly $14 billion health wearables market.
Watch AI/ML Innovations (OTC: AIMLF) (CSE: AIML) NEXT SUPER STOCK Video:
https://www.wallstreetreporter.com/2022/05/31/next-super-stock-ai-ml-billion-dollar-patent/4

AR/AI "SmartGlasses" partnership with Luxotica has the potential for that type of explosive revenue acceleration over the next 18 month.

Paul discusses the GAME CHANGER partnership with $78 Billion EssilorLuxotica to make AR/AI Smart Glasses for Healthcare Apps.

(EssilorLuxotica makes the RayBan Meta smart glasses - and virtually all designer brand eyewear worldwide.)

Watch Paul's demo and you will begin to understand the possibilities and how $AIMLF has a potential path to $5.00 in next 18 months.

Next Super Stock $AIMLF keeps trending higher, amidst a rough market backdrop.

Technical signals for $AIMLF are BULLISH with increasing volume on rising prices.

The charts show a very wide double-bottom pattern, which gives a strong foundation to support a potential +10X. Notably, $AIMLF is trending above the 50 & 200 day moving average.

It appears $AIMLF is just one news release/catalyst away from a major breakout.

With new CEO Paul Duffy in place, $AIMLF is finally executing on it's growth strategy and upside potential.

AI/ML INNOVATIONS INC.
AI/ML Innovations’ Strategic Partner, Tech2Health, Projects
https://aiml-innovations.com/wp-content/uploads/2021/09/AIML-News-Release-July-14-2021.pdf

US$5M Revenue from its First Commercial Contracts
-3 multi-year contracts signed in the first month of operation-
- digital mental health services contracts provide access to 300,000 potential usersJuly 14, 2021 ACCESSWIRE
AI/ML Innovations Inc. (CSE: AIML) (OTCQB: AIMLF) (“AIML” or the “Company”), a company
committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address
urgent societal needs, is pleased to announce that its strategic partner, Tech2Health, a France-based global
provider of proprietary digital mental health and wellness products, has entered into commercial contracts
with three companies to provide digital mental health services to their employees and insured members.
Based on the number of individuals covered and standard industry usage rates, Tech2Health estimates that
these contracts may potentially generate an aggregate total of US$5 million of revenue over the 3-year life
of the contracts. AIML has a binding Letter of Intent to acquire a 70% undivided interest in the North
American rights to Tech2Health’s complete portfolio of products and brands, in addition to a 22.22% equity
interest in Tech2Health’s global operations.

AI / ML Innovations Inc. (AIMLF)

INTERESTING AI / ML INNOVATIONS COMPANY